Article Text

PDF
Original article
Kras and Lkb1 mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cells
  1. Louis Collet1,
  2. Elsa Ghurburrun1,
  3. Nora Meyers1,
  4. Mohamad Assi1,
  5. Boris Pirlot2,
  6. Isabelle A Leclercq2,
  7. Anne Couvelard3,4,
  8. Mina Komuta5,
  9. Jérôme Cros6,
  10. Pieter Demetter7,
  11. Frédéric P Lemaigre1,
  12. Ivan Borbath2,8,
  13. Patrick Jacquemin1
  1. 1 Université catholique de Louvain, de Duve Institute, Brussels, Belgium
  2. 2 Université catholique de Louvain, IREC, Brussels, Belgium
  3. 3 Université Paris Diderot, U1149, Paris, France
  4. 4 Hôpital Bichat, Department of Pathology, AP-HP, DHU UNITY, Paris, France
  5. 5 Université catholique de Louvain, Cliniques universitaires Saint- Luc, Department of Pathology, Brussels, Belgium
  6. 6 Hôpital Beaujon, Department of Pathology, INSERM U1149, Paris, France
  7. 7 Université libre de Bruxelles, Erasme University Hospital, Department of Pathology, Brussels, Belgium
  8. 8 Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium
  1. Correspondence to Dr Ivan Borbath, Université catholique de Louvain ,Cliniques universitaires Saint-Luc, Hepato-Gastroenterology unit, Avenue Hippocrate 10, B-1200 Brussels, Belgium; ivan.borbath{at}uclouvain.be and Dr Patrick Jacquemin, de Duve Institute, Université catholique de Louvain, Brussels B-1200, Belgium; patrick.jacquemin{at}uclouvain.be

Abstract

Objective Pancreatic cancer can arise from precursor lesions called intraductal papillary mucinous neoplasms (IPMN), which are characterised by cysts containing papillae and mucus-producing cells. The high frequency of KRAS mutations in IPMN and histological analyses suggest that oncogenic KRAS drives IPMN development from pancreatic duct cells. However, induction of Kras mutation in ductal cells is not sufficient to generate IPMN, and formal proof of a ductal origin of IPMN is still missing. Here we explore whether combining oncogenic Kras G12D mutation with an additional gene mutation known to occur in human IPMN can induce IPMN from pancreatic duct cells.

Design We created and phenotyped mouse models in which mutations in Kras and in the tumour suppressor gene liver kinase B1 (Lkb1/Stk11) are conditionally induced in pancreatic ducts using Cre-mediated gene recombination. We also tested the effect of β-catenin inhibition during formation of the lesions.

Results Activating Kras G12D mutation and Lkb1 inactivation synergised to induce IPMN, mainly of gastric type and with malignant potential. The mouse lesions shared several features with human IPMN. Time course analysis suggested that IPMN developed from intraductal papillae and glandular neoplasms, which both derived from the epithelium lining large pancreatic ducts. β-catenin was required for the development of glandular neoplasms and subsequent development of the mucinous cells in IPMN. Instead, the lack of β-catenin did not impede formation of intraductal papillae and their progression to papillary lesions in IPMN.

Conclusion Our work demonstrates that IPMN can result from synergy between Kras G12D mutation and inactivation of a tumour suppressor gene. The ductal epithelium can give rise to glandular neoplasms and papillary lesions, which probably both contribute to IPMN formation.

  • pancreatic tumorigenesis
  • pancreatic ductal adenocarcinoma
  • IPMN
  • mucinous neoplasm
View Full Text

Statistics from Altmetric.com

Footnotes

  • LC and EG contributed equally.

  • Contributors Acquisition and statistical analysis of data: LC, EG. Analysis and interpretation of data: LC, EG, AC, IB, PJ. Provision of material: MK, PD. Drafting the manuscript: PJ, LC, EG. Revision of the manuscript: LC, EG, AC, PD, IB, FL, PJ.

  • Funding This work was supported by grants from the Fondation contre le Cancer (Belgium #2014-125 and #2018-078 to FL, and #2016-089 and #2018-076 to PJ), the FRS-FNRS (Belgium; #T007214 to FL and #J002517 to PJ), the Université catholique de Louvain, the Centre du Cancer (Cliniques universitaires St-Luc), the Fonds Maisin, and the COST Action BM1204 EU_Pancreas. LC, EG and NM hold a Télévie fellowship (#74600115 and #7651017).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Author note PJ is senior research associate at the FRS-FNRS (Belgium).

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.